Access to insulin in sub-Saharan Africa is hindered by the absence of structured management programs and multifaceted healthcare delivery challenges.22 These include limited awareness of T1DM, delayed diagnosis, insufficient diagnostic resources, and logistical hurdles in sample transport and processing.22 South African public healthcare, the main provider for diabetes care, struggles with overcrowding, leading to excessive wait times for routine treatments. The gene discussed is INS; the disease is type 1 diabetes mellitus.